Version 1
: Received: 9 February 2023 / Approved: 14 February 2023 / Online: 14 February 2023 (03:18:57 CET)
How to cite:
Rubio-Osornio, M.; León, C. T. G.-D.; Montes, S.; Rubio, C.; Ríos, C.; Monroy-Noyola, A.; Morales-Montor, J. Repurposing Simvastatin in Parkinson's Disease Model: Protection is throughout Modulation of the Neuro-inflammatory Response in the Substantia Nigra. Preprints2023, 2023020227. https://doi.org/10.20944/preprints202302.0227.v1
Rubio-Osornio, M.; León, C. T. G.-D.; Montes, S.; Rubio, C.; Ríos, C.; Monroy-Noyola, A.; Morales-Montor, J. Repurposing Simvastatin in Parkinson's Disease Model: Protection is throughout Modulation of the Neuro-inflammatory Response in the Substantia Nigra. Preprints 2023, 2023020227. https://doi.org/10.20944/preprints202302.0227.v1
Rubio-Osornio, M.; León, C. T. G.-D.; Montes, S.; Rubio, C.; Ríos, C.; Monroy-Noyola, A.; Morales-Montor, J. Repurposing Simvastatin in Parkinson's Disease Model: Protection is throughout Modulation of the Neuro-inflammatory Response in the Substantia Nigra. Preprints2023, 2023020227. https://doi.org/10.20944/preprints202302.0227.v1
APA Style
Rubio-Osornio, M., León, C. T. G. D., Montes, S., Rubio, C., Ríos, C., Monroy-Noyola, A., & Morales-Montor, J. (2023). Repurposing Simvastatin in Parkinson's Disease Model: Protection is throughout Modulation of the Neuro-inflammatory Response in the Substantia Nigra. Preprints. https://doi.org/10.20944/preprints202302.0227.v1
Chicago/Turabian Style
Rubio-Osornio, M., Antonio Monroy-Noyola and Jorge Morales-Montor. 2023 "Repurposing Simvastatin in Parkinson's Disease Model: Protection is throughout Modulation of the Neuro-inflammatory Response in the Substantia Nigra" Preprints. https://doi.org/10.20944/preprints202302.0227.v1
Abstract
Parkinson’s disease is a neurodegenerative disorder characterized by oxidative stress and immune activation in the nigro-striatal pathway. Simvastatin regulates cholesterol metabolism and protects from atherosclerosis disease. Simvastatin or tween-80 was administered 7 days before sterotaxic intrastriatal administration of MPP+ (1-methyl-4-phenylpyridine) in rats. Fluorescent lipidic product formation, dopamine levels, and circling behavior were considered damage markers. Twenty-four h and six days after, the animal group lesioned with MPP+ showed significant damage in relation to the control group. Animals pretreated with simvastatin reduced significantly the MPP+-induced damage compared to MPP+ treated group. As apoptosis promotes neuroinflammation and neuronal degeneration in Parkinson’s disease, and since there is not currently a proteomic map of the Nigro striatum of rats, and assuming a high homology among the identified proteins in other rat tissues, we based the search for rat protein homologs related to the establishment of inflammation response. We demonstrate that most proteins related to inflammation are decreased in the simvastatin-treated rats. Furthermore, differential expression of antioxidant enzymes in striated tissue of rat brains was found in response to simvastatin. These results suggest that simvastatin could prevent striatal MPP+-induced damage and for the first time the molecular mechanisms involved in this protective effect.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
*
